Bystine® is an orally active compound,which can significant improve the inflammatory reaction in asthma patients．It is a leukotriene modifier prescription drug，and a highly selective leukotriene receptor antagonist．Montelukast is rapidly absorbed following oral administration，and relieve the leukotriene-mediated inflammatory condition and bronchospasm by binds with leukotriene receptors，and then improve asthma symptom and pulmonary function. Bystine® can be used as an alternative pharmacotherapy for mild asthma patients，or used with other medicine as a combination treatment for moderate to severe asthma patients，and especially effective for those patients with asthma and allergic rhinitis. Montelukast is also indicated for patient with aspirin induced asthma(AIA) and exercise induced asthma(EIA).
Bystine® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. it＇s effective in improving airway function in asthmatics with documented aspirin sensitivity，and also effective in prevention of exercise-induced bronchoconstriction (EIB). Bystine® is indicated for the relief of symptoms of seasonal allergic rhinitis in patients.